Acromegaly Drug Pipeline — PatSnap Eureka
Acromegaly Drug Pipeline: Somatostatin Analogs, Pasireotide & GH Receptor Antagonists
The acromegaly therapeutic landscape is evolving rapidly. From first-generation somatostatin receptor ligands to second-generation pasireotide and novel chimeric compounds, PatSnap Eureka synthesizes patent and literature evidence across the full GH/IGF-1 axis pipeline.
The GH/IGF-1 Axis: Central Target in Acromegaly
Acromegaly is a rare, chronic endocrine disorder caused predominantly by GH-secreting pituitary neuroendocrine tumors (PitNETs), resulting in pathological elevation of GH and downstream hepatic IGF-1 hypersecretion. Across the dataset analyzed by PatSnap Eureka, the GH/IGF-1 axis constitutes the central therapeutic target, with normalization of both biomarkers serving as the primary endpoint across clinical and translational studies.
Transcriptomic analyses identify at least three distinct subgroups of somatotroph PitNETs, differing in GNAS mutation status, granulation density, NR5A1/SF-1 co-expression, and GIPR expression — each with implications for drug responsiveness. Somatic GNAS mutations are present in approximately 40% of GH-secreting tumors and correlate with transcriptomic subgrouping and clinical behavior.
Key molecular targets include somatostatin receptors (SSTR1–5), the GH receptor (GHR), IGF-1 receptor (IGF-1R), AIP gene mutations, and EMT-related markers such as E-cadherin. Understanding which subtype a patient harbors is increasingly central to selecting optimal therapy — a principle driving the personalized IP analytics approach within PatSnap Eureka. Authoritative guidance on rare endocrine tumors is maintained by organizations including the World Health Organization.
Approved & Investigational Agents in the Acromegaly Pipeline
From first-line somatostatin analogs to emerging chimeric molecules, the acromegaly pipeline spans approved, preclinical, and IP-stage approaches targeting the GH/IGF-1 axis.
First-Generation SRLs: Octreotide LAR & Lanreotide Autogel
These agents act primarily through SSTR2 activation, suppressing GH secretion and inducing antiproliferative effects via direct receptor signaling and indirect antiangiogenic mechanisms. Tumor volume reduction is more pronounced as primary therapy. Comparative studies indicate equivalence between octreotide LAR and lanreotide Autogel on GH/IGF-1 normalization. Learn more about life sciences drug intelligence on PatSnap.
Biochemical control: 20–70% of patientsPasireotide LAR (SOM230; Novartis)
A multireceptor SRL with highest affinity for SSTR5 > SSTR2 > SSTR3 > SSTR1. Phase III PAOLA study data document superiority over octreotide LAR in treatment-naive patients. Particularly effective in AIP-mutated acromegaly, sparsely granulated adenomas with low SSTR2/high SSTR5, and plurihormonal tumors. Key safety signal: hyperglycemia via SSTR5-mediated inhibition of insulin and GLP-1 secretion.
358 patients randomized across 27 countriesPegvisomant
The only GH receptor antagonist in this dataset. Acts by competitively blocking GH receptor dimerization through a modified, pegylated GH molecule (mutation at glycine-120). Superior IGF-1 normalization rates of 65–90% compared to monotherapy SRLs. No direct antiproliferative pituitary tumor effects — combination with SRLs required for tumor volume management. Real-world utilization limited by cost and monitoring requirements.
IGF-1 normalization: 65–90%Dopamine Agonists: Cabergoline & Bromocriptine
D2 dopamine receptor (DRD2) agonists suppressing GH and prolactin secretion in somatotroph tumor cells. Cabergoline combined with octreotide LAR or lanreotide achieves IGF-1 normalization in approximately 32% of patients. Primary utility in co-secretion of prolactin or partial response to SRLs. DRD2 expression serves as a pharmacodynamic predictor in somatotroph tumors.
IGF-1 normalization with SRL combo: 32%Chimeric Somatostatin–Dopamine Compounds (BIM23B065)
Bifunctional chimeric molecules targeting both somatostatin and dopamine receptors simultaneously. BIM23B065 demonstrates suppression of GH secretion and inhibition of ERK1/2 and CREB phosphorylation in GH3 somatotroph cells. The related compound BIM-23A760 is referenced in the context of MAPK pathway modulation in pituitary adenomas.
Stage: Preclinical / Early InvestigationalAntisense Oligonucleotides Targeting GHR (Antisense Therapeutics Ltd)
A combination strategy pairing somatostatin analogs with antisense oligonucleotides directed against the GH receptor (EP patent, inactive). Designed to reduce serum/plasma IGF-1 by simultaneously suppressing GH secretion and impairing GHR-mediated IGF-1 induction in the liver. Claims extend to acromegaly, gigantism, diabetic retinopathy/nephropathy, and GH-responsive cancers. No clinical signals retrieved for this specific combination.
Stage: IP Stage · Preclinical rationaleKey Efficacy & Biomarker Signals Across the Pipeline
PatSnap Eureka synthesizes patent and literature data to surface the quantitative signals that matter most for acromegaly drug development decisions.
Biochemical Control Rates by Therapeutic Modality
IGF-1 normalization rates vary substantially across acromegaly treatment options, with pegvisomant achieving the highest rates in monotherapy.
Acromegaly Pipeline: Development Stage Distribution
Of 8 distinct therapeutic modalities identified, 3 are approved, 4 are preclinical/early investigational, and 1 is at IP stage.
The Most-Cited Drug in the Dataset: Pasireotide LAR
Pasireotide (SOM230; Novartis) is the most extensively discussed drug in this dataset, appearing across more than 15 distinct retrieved papers. As a multireceptor SRL with highest affinity for SSTR5 > SSTR2 > SSTR3 > SSTR1, it is mechanistically distinct from octreotide and lanreotide. Phase III data from the PAOLA study and head-to-head comparative trials document superiority of pasireotide LAR over octreotide LAR in achieving biochemical control in treatment-naive patients — a trial enrolling 358 medically naive patients across 84 sites in 27 countries.
A critical safety signal documented across multiple papers is pasireotide-associated hyperglycemia, attributed to inhibition of insulin and GLP-1 secretion via SSTR5 engagement in pancreatic beta cells — not through worsening insulin resistance. Risk factor analysis was conducted across 178 treatment-naive and 125 SRL-uncontrolled patients in prospective studies C2305 and C2402. The NIH maintains extensive resources on endocrine tumor management relevant to this safety profile.
Pasireotide demonstrates particular utility in AIP-mutated acromegaly with primary resistance to fg-SRLs, sparsely granulated adenomas with low SSTR2/high SSTR5 expression, and plurihormonal tumors co-secreting GH, prolactin, and/or ACTH. PatSnap's IP analytics platform enables teams to track Novartis's full somatostatin receptor ligand portfolio.
Molecular Targets, Biomarkers & Drug Response Predictors
Retrieved immunohistochemical, transcriptomic, and molecular studies identify actionable biomarkers that predict SRL response and guide treatment selection.
| Target / Biomarker | Biological Role | Clinical Relevance | Status |
|---|---|---|---|
| SSTR2 | Dominant somatostatin receptor; primary target of fg-SRLs | High expression predicts response to octreotide/lanreotide; low expression associated with fg-SRL resistance | Validated |
| SSTR5 | Additional somatostatin receptor; principal additional target of pasireotide | High expression (with low SSTR2) predicts favorable response to pasireotide; mechanistic basis for second-gen SRL differentiation | Validated |
| AIP (Aryl Hydrocarbon Receptor-Interacting Protein) | Tumor suppressor; mutations cause hereditary, early-onset acromegaly | AIP mutations predict primary SST2-SRL resistance; pasireotide may be preferred therapeutic option | Validated |
| E-cadherin / SNAI1 | EMT markers; E-cadherin loss and high SNAI1 indicate epithelial-mesenchymal transition | Low E-cadherin predicts poor SRL response and tumor invasiveness; SNAI1 high expression correlates with invasive, non-responsive tumors | Validated |
| GNAS mutation | Somatic Gs-alpha subunit mutation; present in ~40% of GH-secreting tumors | Correlates with transcriptomic subgrouping and clinical behavior; potential stratification marker | Investigational |
| miR-29c-3p | MicroRNA; downregulated in patients with inadequate SSA control | Circulating miRNA as potential biomarker of SRL resistance; differential miRNA profiles correlate with SSA responsiveness | Investigational |
Track Acromegaly Biomarker Patents & Publications
PatSnap Eureka searches across patents and literature to surface the biomarker signals that matter for your pipeline decisions.
Beyond SRLs: Molecular-Targeted & Repurposed Agents
Retrieved results identify several investigational agents targeting novel pathways in somatotroph tumors, from tyrosine kinase inhibitors to GHRH antagonists and chemotherapy for aggressive disease.
GHRH Antagonists: MIA-602 & MIA-690
MIAMI-class GHRH antagonists targeting the GHRH receptor at the hypothalamic-pituitary level. Demonstrate inhibition of cell viability and promotion of apoptosis in GH3-GHRHR pituitary adenoma cells and ACTH-secreting AtT20 cells. Currently at preclinical stage in retrieved data. Research led by University of Ferrara.
Imatinib (Tyrosine Kinase Inhibitor)
Targets c-Kit, PDGFR-α/β, and VEGF-R expressed in somatotropinomas. Retrieved ex vivo studies in human somatotropinomas showed suppression of GH secretion. Research conducted at PGIMER, Chandigarh. Represents a repurposing signal for an established oncology agent in acromegaly.
Who Is Driving Acromegaly Innovation?
Retrieved results are dominated by academic medical centers and university hospital groups, with limited commercial patent activity. The dataset contains one assignee-attributed patent from Antisense Therapeutics Ltd (EP jurisdiction), while the remainder of entries are peer-reviewed academic literature — indicating that innovation in this field is predominantly literature-driven.
Novartis Pharmaceuticals is the sponsor of pasireotide clinical trials (C2305, PAOLA/C2402) explicitly cited across multiple retrieved papers. The University of Ferrara contributes multiple papers covering pegvisomant, GHRH antagonists, and SRL escalation strategies. Erasmus University Medical Center, Rotterdam is represented for pegvisomant combination therapy and IGF-1R resistance mechanisms.
The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw contributed two transcriptomic classification studies of somatotroph PitNETs and a personalized treatment outcome analysis across 153 patients. PatSnap customers in pharma and biotech use Eureka to monitor academic institution output and identify partnering opportunities. The European Patent Office maintains the patent register for the Antisense Therapeutics EP filing referenced in this dataset.
Track the full assignee landscape for acromegaly and pituitary tumor drug development using PatSnap's IP analytics tools, which cover 120+ countries and 2B+ data points.
Acromegaly Drug Pipeline — Key Questions Answered
Octreotide long-acting release (LAR) and lanreotide Autogel are the first-line standard medical therapy in acromegaly. These agents act primarily through SSTR2 activation, suppressing GH secretion and inducing antiproliferative effects. Biochemical control is achieved in approximately 20–70% of patients with first-generation SRLs, leaving a substantial subset requiring escalation or alternative therapy.
Pasireotide is a multireceptor SRL with highest affinity for SSTR5 > SSTR2 > SSTR3 > SSTR1, distinguishing it mechanistically from octreotide and lanreotide, which act primarily through SSTR2. Phase III data from the PAOLA study and head-to-head comparative trials document superiority of pasireotide LAR over octreotide LAR in achieving biochemical control in treatment-naive patients.
A critical safety signal is pasireotide-associated hyperglycemia, attributed to inhibition of insulin and GLP-1 secretion via SSTR5 engagement in pancreatic beta cells rather than through worsening insulin resistance.
Retrieved evidence consistently indicates superior IGF-1 normalization rates of 65–90% with pegvisomant compared to monotherapy SRLs. The LA-SSA + pegvisomant combination normalizes IGF-1 in virtually all patients when adequate dosing is applied.
AIP mutations are associated with aggressive, hereditary acromegaly with poor response to SST2-preferential SRLs. AIP-mutant acromegaly is a clinically distinct subpopulation with early onset, macroadenomas, and primary SST2-SRL resistance, for which pasireotide may represent a preferred therapeutic option.
Chimeric somatostatin–dopamine compounds are bifunctional molecules targeting both somatostatin and dopamine receptors simultaneously. BIM23B065 is highlighted as a novel compound demonstrating suppression of GH secretion and inhibition of ERK1/2 and CREB phosphorylation in GH3 somatotroph cells. These agents are currently at preclinical/early investigational stage.
Still have questions about the acromegaly pipeline? Let PatSnap Eureka answer them instantly.
Ask Eureka About Acromegaly DrugsAccelerate Your Acromegaly Drug Discovery with AI-Powered Intelligence
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D across somatostatin analogs, GH receptor antagonists, and the full pituitary tumor pipeline.
References
- Transcriptomic Classification of Pituitary Neuroendocrine Tumors Causing Acromegaly — Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw (2022)
- Somatostatin Receptor Subtype Expression in Patients with Acromegaly and Complicated Clinical Course — Kepler University Hospital, Linz (2021)
- Treatment of acromegaly by rosiglitazone via upregulating 15-PGDH in both pituitary adenoma and liver — Sun Yat-sen University Cancer Center (2021)
- Mechanisms of putative IGF-I receptor resistance in active acromegaly — Erasmus MC, Rotterdam (2020)
- AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients — CHU de Liège (2019)
- E-cadherin expression is associated with somatostatin analogue response in acromegaly — Hospital Universitario Reina Sofía, Córdoba (2019)
- The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly — University Federico II of Naples (2015)
- Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study — Novartis Pharmaceuticals Corporation (2014)
- Impairment in insulin secretion without changes in insulin resistance explains hyperglycemia in patients with acromegaly treated with pasireotide LAR — Hôpital Bicêtre, Paris-Saclay (2022)
- Risk factors and management of pasireotide-associated hyperglycemia in acromegaly — Peking Union Medical College Hospital (2020)
- Pegvisomant in acromegaly: an update — University of Ferrara (2017)
- Combined treatment of somatostatin analogues with pegvisomant in acromegaly — Erasmus University Medical Center, Rotterdam (2015)
- Effects of combination therapy: somatostatin analogues and dopamine agonists on GH and IGF1 levels in acromegaly — Iuliu Hatieganu University, Cluj-Napoca (2015)
- Therapeutic Effect of a Novel Chimeric Molecule Targeting Both Somatostatin and Dopamine Receptors on Growth Hormone-Secreting Pituitary Adenomas — Yonsei University College of Medicine, Seoul (2020)
- Antagonists of Growth Hormone-Releasing Hormone Inhibit the Growth of Pituitary Adenoma Cells by Hampering Oncogenic Pathways and Promoting Apoptotic Signaling — University of Ferrara (2021)
- Imatinib Inhibits GH Secretion From Somatotropinomas — PGIMER, Chandigarh (2018)
- Temozolomide and Capecitabine Treatment for an Aggressive Somatotroph Pituitary Tumor — Moriyama Memorial Hospital, Tokyo (2022)
- Pasireotide in the Personalized Treatment of Acromegaly — Germans Trias Hospital, Badalona (2021)
- Implications of Heterogeneity of Epithelial-Mesenchymal States in Acromegaly Therapeutic Pharmacologic Response — Hospital Vall d'Hebron, Barcelona (2022)
- Clinical, hormonal and pathomorphological markers of somatotroph pituitary neuroendocrine tumors predicting the treatment outcome in acromegaly — Maria Sklodowska-Curie National Research Institute of Oncology (2022)
- World Health Organization — Endocrine Tumor Classification and Rare Disease Resources
- National Institutes of Health — Acromegaly and Pituitary Tumor Research Resources
- European Patent Office — Patent Register for Acromegaly-Related IP Filings
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.